Seeking Alpha

Watson Pharmaceuticals (WPI +2.8%) gains on an upgrade to Outperform on valuation at Wells...

Watson Pharmaceuticals (WPI +2.8%) gains on an upgrade to Outperform on valuation at Wells Fargo. Wells says that on deeper analysis, it has higher confidence in the company's ability to hit EPS targets following the Actavis acquisition. The firm also raises its price target range to $84 - $90 from $75 - $79.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs